X Henry Hu

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate
    X Henry Hu
    Outcomes Research and Management, Merck and Co, Inc, West Point, PA 19486, USA
    J Clin Psychiatry 65:959-65. 2004
  2. ncbi EuroQol (EQ-5D) health utility scores for patients with migraine
    Ruifeng Xu
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA, USA
    Qual Life Res 20:601-8. 2011
  3. ncbi Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model
    William C Gerth
    Worldwide Outcomes Research, Merck and Co, Inc, Whitehouse Station, New Jersey 08889, USA
    J Occup Environ Med 46:48-54. 2004
  4. ncbi Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study
    Christopher F Bell
    Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania 19486, USA
    Clin Ther 28:872-80. 2006
  5. ncbi Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study
    Roger Cady
    Headache Care Center, Primary Care Network, Inc, Springfield, MO, USA
    Headache 44:900-7. 2004
  6. ncbi Treatment of migraine with rizatriptan: when to take the medication
    X Henry Hu
    Outcomes Research and Management, US Human Health, Merck and Co, Inc, West Point, PA, USA
    Headache 42:16-20. 2002
  7. ncbi Does early migraine treatment shorten time to headache peak and reduce its severity?
    X Henry Hu
    Global Outcomes Research, Global Human Health, Merck and Co, Inc, Whitehouse Station, NJ, USA
    Headache 48:914-20. 2008
  8. ncbi Acute migraine treatment with oral triptans and NSAIDs in a managed care population
    Daisy S Ng-Mak
    Outcomes Research and Management, Merck and Co, Inc, West Point, PA, USA
    Headache 48:1176-85. 2008
  9. ncbi Real-world experiences in migraine therapy with rizatriptan
    Dara Jamieson
    University of Pennsylvania, Philadelphia 19486, USA
    Headache 43:223-30. 2003
  10. ncbi Discontinuation of use and switching of antidepressants: influence of patient-physician communication
    Scott A Bull
    Division of Research, Kaiser Permanente Medical Care Program, 2000 Broadway, Oakland, CA 94612 2304, USA
    JAMA 288:1403-9. 2002

Collaborators

Detail Information

Publications11

  1. ncbi Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate
    X Henry Hu
    Outcomes Research and Management, Merck and Co, Inc, West Point, PA 19486, USA
    J Clin Psychiatry 65:959-65. 2004
    ..Selective serotonin reuptake inhibitors (SSRIs) are widely used as the first-line treatment for depression. Information regarding their side effects is mostly based on controlled clinical trials...
  2. ncbi EuroQol (EQ-5D) health utility scores for patients with migraine
    Ruifeng Xu
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA, USA
    Qual Life Res 20:601-8. 2011
    ..We evaluated within-attack health utilities among acute migraine patients experiencing different grades of headache severity...
  3. ncbi Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model
    William C Gerth
    Worldwide Outcomes Research, Merck and Co, Inc, Whitehouse Station, New Jersey 08889, USA
    J Occup Environ Med 46:48-54. 2004
    ..S. company. There is a substantial productivity cost burden of migraine from a U.S. employer perspective. These productivity costs can be reduced significantly by treating migraine headaches with rizatriptan...
  4. ncbi Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study
    Christopher F Bell
    Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania 19486, USA
    Clin Ther 28:872-80. 2006
    ..Patients reported greater satisfaction with and preference for rizatriptan...
  5. ncbi Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study
    Roger Cady
    Headache Care Center, Primary Care Network, Inc, Springfield, MO, USA
    Headache 44:900-7. 2004
    ..Additional studies at other usual care settings may be needed to confirm the findings...
  6. ncbi Treatment of migraine with rizatriptan: when to take the medication
    X Henry Hu
    Outcomes Research and Management, US Human Health, Merck and Co, Inc, West Point, PA, USA
    Headache 42:16-20. 2002
    ..Taking rizatriptan at the onset of headache was associated with more rapid relief of headache and reversal of functional disability...
  7. ncbi Does early migraine treatment shorten time to headache peak and reduce its severity?
    X Henry Hu
    Global Outcomes Research, Global Human Health, Merck and Co, Inc, Whitehouse Station, NJ, USA
    Headache 48:914-20. 2008
    ..To explore whether early treatment would shorten the duration of headache from headache onset to its peak and reduce headache severity at peak...
  8. ncbi Acute migraine treatment with oral triptans and NSAIDs in a managed care population
    Daisy S Ng-Mak
    Outcomes Research and Management, Merck and Co, Inc, West Point, PA, USA
    Headache 48:1176-85. 2008
    ..To describe the use of oral triptans with or without nonsteroidal anti-inflammatory drugs (NSAIDs) for acute migraine treatment in a managed care population and its potential impact on functionality...
  9. ncbi Real-world experiences in migraine therapy with rizatriptan
    Dara Jamieson
    University of Pennsylvania, Philadelphia 19486, USA
    Headache 43:223-30. 2003
    ..CONCLUSIONS: In this "real-world" setting involving a patient population selected by clinicians, rizatriptan appeared to offer better treatment outcomes than those from prior treatments with other oral migraine medications...
  10. ncbi Discontinuation of use and switching of antidepressants: influence of patient-physician communication
    Scott A Bull
    Division of Research, Kaiser Permanente Medical Care Program, 2000 Broadway, Oakland, CA 94612 2304, USA
    JAMA 288:1403-9. 2002
    ..Although current depression treatment guidelines recommend continuing antidepressant therapy for at least 4 to 9 months, many patients discontinue treatment prematurely, within 3 months...
  11. ncbi Postoperative nausea and vomiting following inpatient surgeries in a teaching hospital: a retrospective database analysis
    Ashraf S Habib
    Duke University Medical Center, Durham, NC 27710, USA
    Curr Med Res Opin 22:1093-9. 2006
    ..CONCLUSIONS: PONV remain a significant problem postoperatively and often persists beyond PACU discharge. The presence of PONV is associated with increased length of PACU stay and greater resource utilization and costs...